{'fraction_non_alphanumeric': 0.03492786636294609, 'fraction_numerical': 0.01366742596810934, 'mean_word_length': 5.073732718894009, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Unusual Sarcoma Arising in Lymphoedema

in a variety of other rheumatic diseases. Risks of carcinogenesis and leukaemogenesis are real, and should be compared to those from cytotoxic therapy (Casciato & Scoci 1979). Bone marrow toxicity is unavoidable and may be potentiated by previous cytotoxic therapy or irradiation, and this may be a life-threatening complication (Morgan et al. 1985) if caution in planning dosage is not observed. Anti-Jo-l-antibody, an autoantibody directed against histidyl-t-RNA synthetase (Matthews & Bernstein 1983), is specific for myositis and was found in 25% of patients with dermatomyositis or polymyositis seen at Hammersmith Hospital. It is not found in childhood or malignancy-associated myositis, but does seem to, 'label' a subset of patients with interstitial lung disease (Bernstein et al. 1984) and mild overlap features such as Raynaud's phenomenon, arthritis and sicca syndrome. Although the beneficial effects of TBI may be short-lived, it can be a useful adjunct to treatment in life-threatening disease where conventional therapy has failed. Acknowledgments: We are grateful to Dr J Cuddigan who referred this patient, and to Dr K E Halnan, Director of the Radiotherapy Department, RPMS, for planning his treatment. We also thank Ms J Coppen for providing myometric data.